Healthcare Realty Trust Incorporated (HR) Analysts See $0.40 EPS


Investors sentiment decreased to 1.08 in 2018 Q4. Its down 0.06, from 1.14 in 2018Q3. It dived, as 19 investors sold Healthcare Realty Trust Incorporated shares while 60 reduced holdings. 25 funds opened positions while 60 raised stakes. 118.69 million shares or 1.24% more from 117.24 million shares in 2018Q3 were reported.
State Common Retirement Fund has 0.02% invested in Healthcare Realty Trust Incorporated (NYSE:HR) for 377,913 shares. 769 were accumulated by Duncker Streett & Incorporated. Eaton Vance Mngmt holds 376,765 shares. Advsr Asset invested in 0% or 1,742 shares. 1,630 were accumulated by Pinebridge Investments Lp. Aperio Grp Ltd Liability Co holds 45,784 shares. Gemmer Asset Mgmt Ltd Limited Liability Company holds 0% in Healthcare Realty Trust Incorporated (NYSE:HR) or 266 shares. Destination Wealth Mgmt holds 500 shares or 0% of its portfolio. Price T Rowe Assoc Md stated it has 0.04% of its portfolio in Healthcare Realty Trust Incorporated (NYSE:HR). Fil Limited owns 0.05% invested in Healthcare Realty Trust Incorporated (NYSE:HR) for 976,500 shares. Goldman Sachs Gp Inc holds 4.60 million shares or 0.04% of its portfolio. 23,845 were reported by First Advsr L P. 260,264 were reported by Parametric Port Associates Ltd Com. Bridgewater Limited Partnership has invested 0% in Healthcare Realty Trust Incorporated (NYSE:HR). The Switzerland-based Swiss Bancorporation has invested 0.01% in Healthcare Realty Trust Incorporated (NYSE:HR).

Since November 21, 2018, it had 0 buys, and 6 insider sales for $1.24 million activity. The insider Hull Robert E sold $136,504. SINGLETON JOHN KNOX also sold $410,237 worth of Healthcare Realty Trust Incorporated (NYSE:HR) shares. Lyle Peter F SR sold 3,298 shares worth $100,391.

Analysts expect Healthcare Realty Trust Incorporated (NYSE:HR) to report $0.40 EPS on May, 2.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.4 EPS. HR’s profit would be $51.48 million giving it 19.16 P/E if the $0.40 EPS is correct. After having $0.40 EPS previously, Healthcare Realty Trust Incorporated’s analysts see 0.00 % EPS growth. The stock decreased 0.36% or $0.11 during the last trading session, reaching $30.66. About 525,011 shares traded. Healthcare Realty Trust Incorporated (NYSE:HR) has risen 17.67% since April 26, 2018 and is uptrending. It has outperformed by 13.30% the S&P500.

Healthcare Realty Trust Incorporated (NYSE:HR) Ratings Coverage

Among 2 analysts covering Healthcare Realty Trust (NYSE:HR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Healthcare Realty Trust had 4 analyst reports since November 13, 2018 according to SRatingsIntel. Raymond James upgraded Healthcare Realty Trust Incorporated (NYSE:HR) on Tuesday, January 8 to “Market Perform” rating. Mizuho upgraded the stock to “Buy” rating in Tuesday, November 13 report.

Healthcare Realty Trust is a real estate investment trust that integrates owning, managing, financing and developing income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2017, the Company owned 197 real estate properties in 26 states totaling 14.4 million square feet and was valued at approximately $5.2 billion. The company has market cap of $3.95 billion.

More notable recent Healthcare Realty Trust Incorporated (NYSE:HR) news were published by: which released: “Healthcare Realty Trust: 4.1% Dividend And Long-Term Upside Potential – Seeking Alpha” on November 19, 2018, also with their article: “Orange Business Services Launches its HR Innovation Lab to Promote Co-Innovation Within the HR Ecosystem – Business Wire” published on April 19, 2019, published: “FDA OKs use of Pfizer’s Ibrance in male patients – Seeking Alpha” on April 04, 2019. More interesting news about Healthcare Realty Trust Incorporated (NYSE:HR) were released by: and their article: “Professionals in Charlotte among most likely to land a job without required skills, survey says – Charlotte Business Journal” published on April 10, 2019 as well as‘s news article titled: “European Commission OKs new use of AstraZeneca’s Lynparza – Seeking Alpha” with publication date: April 10, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Read Full Article

قالب وردپرس


Please enter your comment!
Please enter your name here